![icad investor relations icad investor relations](https://cdn0.scrvt.com/39b415fb07de4d9656c7b516d8e2d907/1800000005712658/439bb490c8b1/v/fd4ef0c0df82/mammogram-with-CAD_BINews_computer-aided-detection_workflow_1800000005712658.jpg)
The information we post on social media could be deemed to be material information.
![icad investor relations icad investor relations](https://i.vimeocdn.com/filter/overlay?src0=https:%2F%2Fi.vimeocdn.com%2Fvideo%2F884221717_1280x685&src1=https:%2F%2Ff.vimeocdn.com%2Fimages_v6%2Fshare%2Fplay_icon_overlay.png)
We use these channels, as well as social media, to communicate with our shareholders and the public about our company, products, and other matters. Please note that we announce material information to our investors using our website, SEC filings, press releases, public conference calls, and webcasts.
#Icad investor relations tv
Besides IR application, ICAD has also developed the application of smart remote control for TV and gaming. This is a value-added and add-on function for mobile phones so that the mobile phones can control home appliances. Whether you are a long-time shareholder or just beginning to consider an investment in our company, we are committed to providing you with useful information and convenient tools to help you make informed decisions about your investment. ICAD has developed an application of infra-red ('IR') remotecontrol embedded in mobile phone. We are also advancing several yield traits we have developed in crops such as Camelina, canola, soybean, and corn. Leveraging our Trait Factory and CRISPR technology, we design precise alterations to gene activity and the flow of carbon in plants to produce higher yields with lower inputs of land, water, or fertilizer. Camelina is our platform crop for producing oil, high-protein meal, and PHA bioplastic while also enabling us to identify new traits for improved yield and field performance. Arrgghh.With environmental sustainability and global food security in mind, we are developing Camelina-based biotechnology to improve the yield and performance of Camelina and other major food and feed crops. ICAD Receives FDA Approval for Digital CAD with Nice bounces today for ICAD and CVSL huh? Positive moving up lots of room to move 7.13 $ICAD Chart - BULLISH HARAMI reversal pattern is I hear that ICAD and SSH are competitors? Looking forward to hearing when Powerlook Tomo 2.0 $ICAD on the rise with imminent submission of ICAD just a beautiful breakout on this bio beast!!! News: $ICAD iCAD to Highlight ProFound AI(TM) SolutionĪI technology for cancer detection is very interesting. News: $ICAD SimonMed Imaging Implements the First FDA-Cleared News: $ICAD iCAD's ProFound AI(TM) for 2D Mammography News: $ICAD iCAD Reports Second Quarter 2019 Financial Results Through the Inovalon ONE® Platform, Inovalon brings to the marketplace a national-scale capability to interconnect with the healthcare ecosystem, aggregate and analyze data in real time, and empower the application of resulting insights to drive meaningful impact at the point of care.
![icad investor relations icad investor relations](https://media.glassdoor.com/lst2x/900/icad-office.jpg)
Very quiet board given the recent performance. Inovalon is a leading provider of cloud-based platforms empowering data-driven healthcare. JUST IN: $ICAD iCAD's IORT Excluded from CMS's Baby'sīreaking News: $ICAD iCAD Responds to CMS' Finalized Got out breakeven yesterday due to impending Death We have an industry-leading Research and Development team giving iCAD a strong base of intellectual property as is evident in the 22 CAD-related patents awarded and the additional 20 patents in process. For more information, call (877) iCADnow. iCAD’s solutions aid in the early detection of the most prevalent cancers including breast, colon, prostate and in the future, lung cancer.
![icad investor relations icad investor relations](https://i.vimeocdn.com/filter/overlay?src0=https:%2F%2Fi.vimeocdn.com%2Fvideo%2F893070562_1280x685&src1=https:%2F%2Ff.vimeocdn.com%2Fimages_v6%2Fshare%2Fplay_icon_overlay.png)
Since receiving FDA approval for the Company’s first breast cancer detection product in 2002, over 3,100 iCAD systems have been placed in healthcare practices worldwide. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography (DR) and computed radiography (CR), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT). is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier.